The Analyst Verdict: Biogen In The Eyes Of 12 Experts
Portfolio Pulse from Benzinga Insights
Over the past three months, 12 analysts have shared their evaluations of Biogen (NASDAQ:BIIB), revealing a mix of bullish and somewhat bullish outlooks. The average 12-month price target is $311.58, slightly down from the previous $314.82. Analysts have adjusted their ratings and price targets based on recent developments, with some lowering their targets and others maintaining or raising them. Biogen's financial performance shows a decline in revenue but strong profitability and effective cost management.
July 29, 2024 | 4:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Analysts have mixed views on Biogen (NASDAQ:BIIB) with an average 12-month price target of $311.58, slightly down from $314.82. Despite a recent revenue decline, Biogen maintains strong profitability and effective cost management.
The mixed analyst ratings and slight decrease in the average price target suggest a neutral short-term impact on Biogen's stock price. The company's strong profitability and effective cost management provide a positive counterbalance to the revenue decline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100